Antiretroviral News and Research

RSS

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

5 Mar 2011

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Today was the last day of the 18th Conference on Retroviruses and Opportunistic Infections, a key HIV/AIDS research meeting being held at the Hynes Convention Center in Boston from February 27 through March 2. Highlighted below are selected presentations from March 2nd on research supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both components of the National Institutes of Health.

5 Mar 2011

Recent releases in Global Health

The Importance Of Investing In Adolescent Girls: A Lancet editorial examines the challenges adolescent girls living in developing countries face and the work of the U.N. Adolescent Girls Task Force to help young women overcome these barriers.

5 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning "the whole treatment world on its head," according to Dartmouth pediatrician Paul Palumbo.

4 Mar 2011

Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%

Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented today.

4 Mar 2011

ATS releases new report detailing emerging trends in HIV-linked pulmonary disease management

The American Thoracic Society has released a new report detailing recent global changes in the management of human immunodeficiency virus-associated pulmonary disease.

4 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

3 Mar 2011

Adherence counseling during HIV treatment greatly improves patient outcomes

Intensive adherence counseling around the time of HIV treatment initiation significantly reduces poor adherence and virologic treatment failure in sub-Saharan Africa, according to a recent study in PLoS Medicine by Dr. Michael Chung, assistant professor of Global Health at University of Washington, who works at the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya.

3 Mar 2011

Viruses that are natural part of human genome may retrovirus culprit

A retrovirus that inserted itself into the human genome thousands of years ago may be responsible for some cases of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gherig’s disease. The finding, made by Johns Hopkins scientists, may eventually give researchers a new way to attack this universally fatal condition.

2 Mar 2011

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.

2 Mar 2011

Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses

At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports.

2 Mar 2011

Tenofovir gel more effective than oral tablet for HIV treatment: Study

In the first study to make head-to-head comparisons between tenofovir gel and oral tenofovir - two promising approaches for preventing HIV in women - researchers found that daily use of the vaginal gel achieved a more than 100-times higher concentration of active drug in vaginal tissue than did the oral tablet, while, compared to the gel, the tablet used daily was associated with a 20-times higher active drug concentration in blood.

1 Mar 2011

Scientists to launch international working group to tackle HIV

More than 30 scientists gathered for a one-day meeting prior to the 18th Conference on Retroviruses and Opportunistic Infections to launch an international working group on HIV reservoirs and strategies to control them.

1 Mar 2011

Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI

Sangamo BioSciences, Inc. announced today the presentation of positive preliminary clinical data from its Phase 1 trial.

1 Mar 2011

Tenofovir gel may help reduce risk of HIV from anal sex

A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel could help reduce the risk of HIV from anal sex, even though the vaginal gel formulation may not be optimal for rectal use.

28 Feb 2011

Antiepileptic drugs could make HIV drugs less effective

A Michigan State University researcher is looking to uncover the risks of treating seizures in HIV-positive patients, providing much-needed data on possible interactions between antiepileptic drugs and antiretroviral medicines that potentially could make HIV drugs less effective or the disease itself drug resistant.

23 Feb 2011

AHF commends Congressman Hastings for securing additional $42M for AIDS Drug Assistance Programs

AIDS Healthcare Foundation (AHF) today commended United States Congressman Alcee Hastings (D, FL, 23rd District) for authoring, introducing and successfully shepherding a budget amendment to the current year's budget that secures crucial additional funding to address a growing crisis in the nation's AIDS Drug Assistance Programs (ADAP), a network of federal and state funded programs that provide life-saving HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS nationwide.

19 Feb 2011

AHF criticizes President Obama's budget proposal for HIV/AIDS programs

Following the release of his proposed Fiscal Year 2012 budget, AIDS Healthcare Foundation, the largest global AIDS organization, today criticized President Barack Obama and his administration for requests for budget funding levels for HIV/AIDS programs that are grossly inadequate to the need.

18 Feb 2011

Antiretroviral News and Research

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Recent releases in Global Health

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%

ATS releases new report detailing emerging trends in HIV-linked pulmonary disease management

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Adherence counseling during HIV treatment greatly improves patient outcomes

Viruses that are natural part of human genome may retrovirus culprit

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses

Tenofovir gel more effective than oral tablet for HIV treatment: Study

Scientists to launch international working group to tackle HIV

Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI

Tenofovir gel may help reduce risk of HIV from anal sex

Antiepileptic drugs could make HIV drugs less effective

AHF commends Congressman Hastings for securing additional $42M for AIDS Drug Assistance Programs

AHF criticizes President Obama's budget proposal for HIV/AIDS programs

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News